FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3037855256> ?p ?o ?g. }

• W3037855256 endingPage "241" @default.
• W3037855256 startingPage "231" @default.
• W3037855256 abstract "Presentar el primer registro que analiza el perfil clínico de los pacientes tratados en España con evolocumab y la efectividad sobre el perfil lipídico y su seguridad en el «mundo real». Estudio multicéntrico, retrospectivo, observacional, de los pacientes que empezaron tratamiento con evolocumab entre febrero de 2016 y mayo de 2017 en la práctica clínica en unidades de cardiología en España. Se incluyó a 186 pacientes de 31 unidades de cardiología (edad media 60,3 ± 9,8 años; 35,5% con hipercolesterolemia familiar y 94,1% con evento cardiovascular previo). Perfil lipídico basal: colesterol total 219,4 ± 52,2 mg/dL, colesterol-LDL 144,0 ± 49,0 mg/dL, colesterol-HDL 47,7 ± 13,0 mg/dL y triglicéridos 151,0 ± 76,2 mg/dL. En el momento del inicio de evolocumab, el 53,8% estaba tomando estatinas (el 50% presentaba intolerancia a las estatinas, total o parcial) y el 51,1% ezetimiba. En todos los casos se empleó la dosis de evolocumab de 140 mg y, principalmente, cada 2 semanas (97,3%). El cumplimiento terapéutico fue elevado (92,3%). En 6 pacientes (3,2%) se interrumpió el tratamiento, pero solo en uno (0,5%), por posible efecto adverso. Evolocumab redujo significativamente el colesterol total (30,9% a las 2 semanas y 39,3% a las 12 semanas; p < 0,001), colesterol-LDL (44,4 y 57,6%, respectivamente; p < 0,001) y triglicéridos (14,8 y 5,2%; p < 0,001), sin modificar significativamente el colesterol-HDL (6,7 y 2,0%; p = 0,14). En la práctica clínica, evolocumab se asocia con reducciones del colesterol-LDL cercanas al 60% tras 12 semanas de tratamiento, con una tasa de retiradas por efectos adversos muy baja y con un elevado cumplimiento terapéutico. Estos resultados son consistentes con los obtenidos en los ensayos clínicos aleatorizados. To present the first registry used to analyse the clinical profile of patients treated with evolocumab in Spain, including the effectiveness on the lipid profile and safety in the «real world» setting. Multicentre, retrospective, and observational study of patients starting treatment with evolocumab from February 2016 to May 2017 in clinical practice in Spanish cardiology units. A total of 186 patients (mean age 60.3 ± 9.8 years were included, 35.5% with familial hypercholesterolaemia, and 94.1% with a previous cardiovascular event) from 31 cardiology units. Baseline lipid profile: Total cholesterol 219.4 ± 52.2 mg/dL, LDL-cholesterol 144.0 ± 49.0 mg/dL, HDL-cholesterol 47.7 ± 13.0 mg/dL, and triglycerides 151.0 ± 76.2 mg/dL. At the time of initiating evolocumab, 53.8% of patients were taking statins (50% had partial or total intolerance to statins), and 51.1% ezetimibe. In all cases, the dose of evolocumab used was 140 mg, mainly every 2 weeks (97.3%). Evolocumab compliance was high (92.3%). Treatment with evolocumab was interrupted in 6 patients (3.2%), with only 1 (0.5%) due to a probable side effect. Evolocumab significantly reduced total cholesterol (30.9% at week 2, and 39.3% at week 12; P<.001), LDL cholesterol (44.4% and 57.6%, respectively; P<.001), and triglycerides (14.8% and 5.2%, respectively; P<001), with no significant changes in HDL-cholesterol (6.7% and 2.0%; P=.14). In clinical practice, evolocumab is associated with reductions in LDL cholesterol, with nearly 60% after 12 weeks of treatment, and with low rates of interruptions due to side effects and high medication compliance. These results are consistent with those reported in randomised clinical trials." @default.
• W3037855256 created "2020-07-02" @default.
• W3037855256 creator A5005075798 @default.
• W3037855256 creator A5026526010 @default.
• W3037855256 creator A5028115559 @default.
• W3037855256 creator A5033111261 @default.
• W3037855256 creator A5059294683 @default.
• W3037855256 creator A5073886328 @default.
• W3037855256 creator A5083633962 @default.
• W3037855256 date "2020-11-01" @default.
• W3037855256 modified "2023-10-01" @default.
• W3037855256 title "Primer registro nacional sobre la efectividad y seguridad de evolocumab en la práctica clínica en pacientes atendidos en cardiología en España. Estudio RETOSS-CARDIO" @default.
• W3037855256 cites W2019071303 @default.
• W3037855256 cites W2024930123 @default.
• W3037855256 cites W2025941066 @default.
• W3037855256 cites W2105241357 @default.
• W3037855256 cites W2180345246 @default.
• W3037855256 cites W2352723316 @default.
• W3037855256 cites W2465758073 @default.
• W3037855256 cites W2495429586 @default.
• W3037855256 cites W2581290930 @default.
• W3037855256 cites W2596179513 @default.
• W3037855256 cites W2600369610 @default.
• W3037855256 cites W2736112106 @default.
• W3037855256 cites W2740472173 @default.
• W3037855256 cites W2742316776 @default.
• W3037855256 cites W2757199879 @default.
• W3037855256 cites W2762069281 @default.
• W3037855256 cites W2768515494 @default.
• W3037855256 cites W2771818179 @default.
• W3037855256 cites W2774009850 @default.
• W3037855256 cites W2794985857 @default.
• W3037855256 cites W2806953101 @default.
• W3037855256 cites W2884577329 @default.
• W3037855256 cites W2885373563 @default.
• W3037855256 cites W2887473262 @default.
• W3037855256 cites W2897943120 @default.
• W3037855256 cites W2898478644 @default.
• W3037855256 cites W2904210113 @default.
• W3037855256 cites W2904400595 @default.
• W3037855256 cites W2911220948 @default.
• W3037855256 cites W2911702236 @default.
• W3037855256 cites W2922474036 @default.
• W3037855256 cites W2930456645 @default.
• W3037855256 cites W2945235307 @default.
• W3037855256 cites W2945845137 @default.
• W3037855256 cites W2954605165 @default.
• W3037855256 doi "https://doi.org/10.1016/j.arteri.2020.05.002" @default.
• W3037855256 hasPublicationYear "2020" @default.
• W3037855256 type Work @default.
• W3037855256 sameAs 3037855256 @default.
• W3037855256 citedByCount "0" @default.
• W3037855256 crossrefType "journal-article" @default.
• W3037855256 hasAuthorship W3037855256A5005075798 @default.
• W3037855256 hasAuthorship W3037855256A5026526010 @default.
• W3037855256 hasAuthorship W3037855256A5028115559 @default.
• W3037855256 hasAuthorship W3037855256A5033111261 @default.
• W3037855256 hasAuthorship W3037855256A5059294683 @default.
• W3037855256 hasAuthorship W3037855256A5073886328 @default.
• W3037855256 hasAuthorship W3037855256A5083633962 @default.
• W3037855256 hasConcept C126322002 @default.
• W3037855256 hasConcept C2778114629 @default.
• W3037855256 hasConcept C2778163477 @default.
• W3037855256 hasConcept C2780745583 @default.
• W3037855256 hasConcept C29456083 @default.
• W3037855256 hasConcept C2994423189 @default.
• W3037855256 hasConcept C71924100 @default.
• W3037855256 hasConceptScore W3037855256C126322002 @default.
• W3037855256 hasConceptScore W3037855256C2778114629 @default.
• W3037855256 hasConceptScore W3037855256C2778163477 @default.
• W3037855256 hasConceptScore W3037855256C2780745583 @default.
• W3037855256 hasConceptScore W3037855256C29456083 @default.
• W3037855256 hasConceptScore W3037855256C2994423189 @default.
• W3037855256 hasConceptScore W3037855256C71924100 @default.
• W3037855256 hasIssue "6" @default.
• W3037855256 hasLocation W30378552561 @default.
• W3037855256 hasOpenAccess W3037855256 @default.
• W3037855256 hasPrimaryLocation W30378552561 @default.
• W3037855256 hasRelatedWork W1506200166 @default.
• W3037855256 hasRelatedWork W1995515455 @default.
• W3037855256 hasRelatedWork W1999344589 @default.
• W3037855256 hasRelatedWork W2039318446 @default.
• W3037855256 hasRelatedWork W2080531066 @default.
• W3037855256 hasRelatedWork W2748952813 @default.
• W3037855256 hasRelatedWork W2789448498 @default.
• W3037855256 hasRelatedWork W2899084033 @default.
• W3037855256 hasRelatedWork W3032375762 @default.
• W3037855256 hasRelatedWork W3108674512 @default.
• W3037855256 hasVolume "32" @default.
• W3037855256 isParatext "false" @default.
• W3037855256 isRetracted "false" @default.
• W3037855256 magId "3037855256" @default.
• W3037855256 workType "article" @default.